Genmab A/S
GMABHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Genmab A/S focuses on Biotechnology services and products. Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. Valued at $17.63B, GMAB is a large-cap name in its sector. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Market Cap
$17.63B
Beta
0.69
P/E (TTM)
22.09
P/E (Fwd)
15.69
EPS (TTM)
$1.30
EPS (Fwd)
$1.83
ROE
15.0%
ROA
8.5%
Cash
$1.52B
Total Debt
$5.35B
Free CF
$830.4M
52W Change
31.3%
Annual Financials
Cash vs Debt
The company holds $1.52B in cash, though total debt stands at $5.35B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $830.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 15.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.09B (2022) to $3.72B (2025), reflecting a 78% increase over the period.
GMAB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Genmab A/S and its sector.